Latest & greatest articles for methylphenidate

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on methylphenidate or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on methylphenidate and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for methylphenidate

21. OROS methylphenidate (Concerta) for the treatment of children and adults with ADHD

OROS methylphenidate (Concerta) for the treatment of children and adults with ADHD OROS methylphenidate (Concerta) for the treatment of children and adults with ADHD | Therapeutics Initiative Independent Healthcare Evidence > > OROS methylphenidate (Concerta) for the treatment of children and adults with ADHD Introduction Pharmaceutical Services Division (PSD) requested an update to the 2006 Therapeutics Initiative review of Concerta (OROS MPH) for the treatment of children and adults with ADHD (...) . The 2006 report included a systematic review in children and adolescents with ADHD. The recent submission includes additional new information in children and adolescents and also an additional new indication, for the treatment of adult patients with ADHD. Drug OROS methylphenidate is a central nervous system stimulant and a controlled substance under Schedule II. The OROS delivery technology provides a mixture of immediate and delayed release. Within 1 hour, plasma MPH concentrations reach

Therapeutics Letter2010

22. Methylphenidate: new patient information

Methylphenidate: new patient information Methylphenidate: new patient information Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Methylphenidate: new patient information From: Published: 11 January 2010 Therapeutic area: and The design and content of the Patient Information Leaflets for methylphenidate products are being updated with the latest guidance on safe and effective use for patients and carers Article date: January 2010 Methylphenidate is a stimulant (...) treatment for children aged 6 years or older and adolescents with attention-deficit hyperactivity disorder (ADHD). Patient information The design and content of the Patient Information Leaflets for methylphenidate products are being updated with the latest guidance on safe and effective use for patients and carers. This includes a tear-off section for children and adolescents who are taking methylphenidate. This tear-off section includes the most important messages written in an engaging style

MHRA Drug Safety Update2010

23. Side effects of methylphenidate in childhood cancer survivors: a randomized placebo-controlled trial

Side effects of methylphenidate in childhood cancer survivors: a randomized placebo-controlled trial 19564304 2009 06 30 2009 09 22 2017 02 20 1098-4275 124 1 2009 Jul Pediatrics Pediatrics Side effects of methylphenidate in childhood cancer survivors: a randomized placebo-controlled trial. 226-33 10.1542/peds.2008-1855 To investigate the frequency and severity of side effects of methylphenidate among childhood survivors of acute lymphoblastic leukemia and brain tumors and identify predictors (...) of higher adverse effect levels. Childhood cancer survivors (N = 103) identified as having attention and learning problems completed a randomized, double-blind, 3-week, home-crossover trial of placebo, low-dose methylphenidate (0.3 mg/kg; 10 mg twice daily maximum) and moderate-dose methylphenidate (0.6 mg/kg; 20 mg twice daily maximum). Caregivers completed the Barkley Side Effects Rating Scale (SERS) at baseline and each week during the medication trial. Siblings of cancer survivors (N = 49) were

EvidenceUpdates2009 Full Text: Link to full Text with Trip Pro

24. A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain

A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain Hong J, Dilla T, Arellano (...) J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The aim was to evaluate the cost-effectiveness of atomoxetine compared with methylphenidate (immediate and extended release) or no treatment, in Spanish children

NHS Economic Evaluation Database.2009

25. Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder

Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder Koesters M, Becker T, Kilian R, Fegert JM, Weinmann S CRD summary This meta-analysis showed a significant effect of methylphenidate on the symptoms of adult attention-deficit (...) and hyperactivity disorder compared with placebo. The conclusions of this review may not be reliable due to lack of quality assessment and pooling of heterogeneous data. Authors' objectives To review the effectiveness of methylphenidate as a treatment for attention-deficit hyperactivity disorder in adults. Searching The following databases were searched from inception to January 2008: MEDLINE, PsycINFO and the Cochrane Central Register of Controlled Trials (CENTRAL). Search strategies and search terms were

DARE.2009

26. Attention deficit hyperactivity disorder in children: comparative efficacy of traditional Chinese medicine and methylphenidate

Attention deficit hyperactivity disorder in children: comparative efficacy of traditional Chinese medicine and methylphenidate Attention deficit hyperactivity disorder in children: comparative efficacy of traditional Chinese medicine and methylphenidate Attention deficit hyperactivity disorder in children: comparative efficacy of traditional Chinese medicine and methylphenidate Lan Y, Zhang LL, Luo R CRD summary This review identified trials of traditional Chinese medicine compared (...) with methylphenidate in children with attention deficit and hyperactivity disorder. The authors concluded that traditional Chinese medicine may be equal or superior to methylphenidate, but that more research was needed. Several methodological problems with the review may mean that the authors’ conclusions are not reliable. Authors' objectives To summarise existing evidence on the comparative effects of traditional Chinese medicine and methylphenidate for treating children with attention deficit and hyperactivity

DARE.2009

27. Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults

Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults Hardy SE CRD summary The review did not find definitive evidence (...) of effectiveness of methylphenidate in medically ill older adults with depression, fatigue or apathy, although it appeared to be tolerated in the short term. Due to variation in outcomes, methodological flaws in the included studies and shortcomings in the review process, the reliability of the author's conclusions is not clear. Authors' objectives To assess the efficacy and tolerability of methylphenidate for the treatment of depressive symptoms, fatigue and apathy in medically ill older adults and adults

DARE.2009

28. Review: Methylphenidate and psychosocial treatments either alone or in combination reduce ADHD symptoms

Review: Methylphenidate and psychosocial treatments either alone or in combination reduce ADHD symptoms Review: Methylphenidate and psychosocial treatments either alone or in combination reduce ADHD symptoms | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: Methylphenidate and psychosocial treatments either alone or in combination reduce ADHD symptoms Article Text Therapeutics Review: Methylphenidate and psychosocial treatments either alone or in combination reduce ADHD symptoms Statistics from Altmetric.com No Altmetric data available

Evidence-Based Mental Health2009

29. Osmotically released methylphenidate is more effective than atomoxetine in children and adolescents with ADHD

Osmotically released methylphenidate is more effective than atomoxetine in children and adolescents with ADHD Osmotically released methylphenidate is more effective than atomoxetine in children and adolescents with ADHD | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password (...) ? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Osmotically released methylphenidate is more effective than atomoxetine in children and adolescents with ADHD Article Text Therapeutics Osmotically released methylphenidate is more effective than atomoxetine in children and adolescents with ADHD Statistics from Altmetric.com

Evidence-Based Mental Health2009

30. Atomoxetine and Osmotically Released Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder: Acute Comparison and Differential Response

Atomoxetine and Osmotically Released Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder: Acute Comparison and Differential Response 18281409 2008 06 03 2008 06 25 2015 11 19 1535-7228 165 6 2008 Jun The American journal of psychiatry Am J Psychiatry Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. 721-30 10.1176/appi.ajp.2007.05091676 Response to atomoxetine (...) , a nonstimulant norepinephrine-specific reuptake inhibitor, was compared with the effect of osmotic-release oral methylphenidate, a long-acting methylphenidate preparation, in patients with attention deficit hyperactivity disorder (ADHD). In a large placebo-controlled, double-blind study, patients ages 6-16 with ADHD, any subtype, were randomly assigned to receive 0.8-1.8 mg/kg per day of atomoxetine (N=222), 18-54 mg/day of osmotically released methylphenidate (N=220), or placebo (N=74) for 6 weeks

EvidenceUpdates2008

31. Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder

Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder 18434918 2008 05 22 2008 06 11 2013 11 21 1527-5418 47 6 2008 Jun Journal of the American Academy of Child and Adolescent Psychiatry J Am Acad Child Adolesc Psychiatry Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder. 700-8 10.1097/CHI.0b013e31816bffdf Children (...) with attention-deficit/hyperactivity disorder often have varying needs for coverage of their symptoms throughout the day. The objectives of this study were to determine the efficacy, duration of action, and safety of methylphenidate transdermal system worn for variable times by children (ages 6-12) diagnosed with ADHD. Methylphenidate dose was optimized over 5 weeks using 10-, 15-, 20-, or 30-mg patches worn for 9 hours. The efficacy of 4- and 6-hour wear times was then assessed in an Analog Classroom setting during a randomized, placebo

EvidenceUpdates2008

32. Methylphenidate may improve symptoms but does not increase response compared with placebo in preschool children with ADHD

Methylphenidate may improve symptoms but does not increase response compared with placebo in preschool children with ADHD Methylphenidate may improve symptoms but does not increase response compared with placebo in preschool children with ADHD | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your (...) user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Methylphenidate may improve symptoms but does not increase response compared with placebo in preschool children with ADHD Article Text Therapeutics Methylphenidate may improve symptoms but does not increase response compared with placebo in preschool children

Evidence-Based Mental Health2008

33. Methylphenidate poisoning: an evidence-based consensus guideline for out-of-hospital management.

Methylphenidate poisoning: an evidence-based consensus guideline for out-of-hospital management. Methylphenidate poisoning: an evidence-based consensus guideline for out-of-hospital management. | National Guideline Clearinghouse Search Sign In Username or Email * Password * Remember Me Don't have an account? Guideline Summary NGC:005892 This guideline summary has been withdrawn from NGC. Please update your bookmarks. View all withdrawn summaries in the . About NGC Guideline Summaries NGC's

American Association of Poison Control Centers2008

34. Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in the Netherlands

Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in the Netherlands Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in the Netherlands Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder (...) suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in the Netherlands Faber A, van Agthoven M, Kalverdijk L J, Tobi H, de Jong-van den Berg L T, Annemans L, Postma M J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions

NHS Economic Evaluation Database.2008

37. Methylphenidate hydrochloride reduces hyperactivity in children with pervasive development disorders

Methylphenidate hydrochloride reduces hyperactivity in children with pervasive development disorders Methylphenidate hydrochloride reduces hyperactivity in children with pervasive development disorders | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Methylphenidate hydrochloride reduces hyperactivity in children with pervasive development disorders Article Text Therapeutics Methylphenidate hydrochloride reduces hyperactivity in children with pervasive development disorders Statistics from Altmetric.com No Altmetric data available

Evidence-Based Mental Health2007

38. Adding multimodal behavioural therapy to methylphenidate does not improve ADHD outcomes

Adding multimodal behavioural therapy to methylphenidate does not improve ADHD outcomes Adding multimodal behavioural therapy to methylphenidate does not improve ADHD outcomes | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Adding multimodal behavioural therapy to methylphenidate does not improve ADHD outcomes Article Text Therapeutics Adding multimodal behavioural therapy to methylphenidate does not improve ADHD outcomes Statistics from Altmetric.com No Altmetric data available for this article. Request permissions If you wish to reuse any

Evidence-Based Mental Health2007

39. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents

A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents Journals Library An error has occurred in processing

NIHR HTA programme2006

40. Adding psychosocial therapy to methylphenidate may not improve its effectiveness in stimulant responsive children with ADHD

Adding psychosocial therapy to methylphenidate may not improve its effectiveness in stimulant responsive children with ADHD Adding psychosocial therapy to methylphenidate may not improve its effectiveness in stimulant responsive children with ADHD | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Adding psychosocial therapy to methylphenidate may not improve its effectiveness in stimulant responsive children with ADHD Article Text Therapeutics Adding psychosocial therapy to methylphenidate may not improve its effectiveness in stimulant responsive

Evidence-Based Mental Health2006